Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar

Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar
Qu Biologics has started enrolling patients in the RESTORE Phase 2 trial to evaluate its lead investigative immunotherapy, QBECO SSI, in patients with moderate to severe Crohn's disease. The study (NCT03472690) is recruiting up to 20 adult Crohn's patients at three sites in Canada — New Westminster, British Columbia; Vancouver, BC; and Hamilton, Ontario. To apply, patients will be asked 16 questions on a trial questionnaire that will assess their eligibility for the study. All participants must had Crohn's disease for at least three months, and should not have taken biologic therapies 60 days prior to the start of the study. Disease activity must have been previously confirmed by endoscopy and the evaluation of clinical symptoms. In this part of the study, the patients will be treated with 0.1ml QBECO by self-administered subcutaneous injection every other day for up to 52 weeks. At weeks 16, 26, and 52 the effectiveness of the treatment in promoting a positive response, and disease remission, will be assessed by endoscopy. All study-related fees and traveling expenses will be covered by the study's sponsor, Qu Biologics. Those interested in participating in the trial or for more information should contact a clinical trial representative by phone at 1-877-223-8637, by e-mail at [email protected], or by going to the Qu's RESTORE trial webpage here. Pending the results of this
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *